CVTX CV Therapeutics (MM)

- Perindopril marketed as ACEON(R) in United States - STOCKHOLM, Sweden, Sept. 4 /PRNewswire-FirstCall/ -- CV Therapeutics (NASDAQ:CVTX) announced today that patients in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) receiving a treatment regimen of the calcium channel blocker amlodipine plus or minus the angiotensin converting enzyme (ACE) inhibitor perindopril experienced a significant reduction in major cardiovascular endpoints and in all-cause mortality compared to patients receiving a regimen of the beta blocker atenolol plus or minus the diuretic bendroflumethiazide, according to data presented today at the European Society of Cardiology Congress 2005 in Stockholm, Sweden, and published concurrently in The Lancet. ASCOT had been stopped early by the study's steering committee due to the benefits observed from the combination of the newer blood pressure lowering drugs, amlodipine and perindopril. All cause mortality was reduced by 11 percent (p=0.025) with this regimen. In the amlodipine and perindopril based treatment regimen, nearly two-thirds of patients were receiving perindopril at the end of the study. In addition, ASCOT showed that the amlodipine and perindopril based regimen reduced total cardiovascular events and procedures by 16 percent (p